Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Farmaco (Societa Chimica Italiana : 1989)|February 1, 1993
Heterocyclic modulators of the NMDA receptorR Pellicciari, B Natalini, G Costantino, et al.
European Journal of Neurology|May 19, 2017
Relationship between pain and motor and non-motor symptoms in Parkinson's diseaseG Defazio, A Antonini, M Tinazzi, et al.
Neuroscience|July 6, 2010
Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistryA Konradsson-Geuken, H Q Wu, C R Gash, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonistF Moroni, G Lombardi, C Thomsen, et al.
Biochemical and Biophysical Research Communications|November 4, 2000
C60 carboxyfullerene exerts a protective activity against oxidative stress-induced apoptosis in human peripheral blood mononuclear cellsD Monti, L Moretti, S Salvioli, et al.
The Journal of Investigative Dermatology|November 9, 2000
Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosisC Fumelli, A Marconi, S Salvioli, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 9, 2022
Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flowM Marzano, Bruno Fosso, C Colliva, et al.
Marine Environmental Research|April 7, 2020
Macroalgal forest vs sea urchin barren: Patterns of macro-zoobenthic diversity in a large-scale Mediterranean studyS Pinna, L Piazzi, G Ceccherelli, et al.
British Journal of Pharmacology|September 15, 2011
Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymeraseF Moroni, A Cozzi, A Chiarugi, et al.
Current Cancer Drug Targets|May 14, 2010
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agentL Tentori, A Muzi, A S Dorio, et al.
Pageof 10